Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in non-small cell lung cancer. [PDF]
, 2015 We hypothesized that aberrations activating epidermal growth factor receptor (EGFR) via dimerization would be more sensitive to anti-dimerization agents (e.g., cetuximab).
Bazhenova, Lyudmila +6 more
core +3 more sources
GBP1 promotes erlotinib resistance via PGK1‑activated EMT signaling in non‑small cell lung cancer.
International Journal of Oncology, 2020 Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‑TKI), is widely applied as a first‑line treatment for non‑small cell lung cancer (NSCLC) and greatly improves the clinical outcomes of patients.
Lifang Cheng +3 more
semanticscholar +1 more source
Scientific Reports, 2022 The goals of this study were to identify transcriptomic changes that arise in basal-like breast cancer cells during the development of resistance to epidermal growth factor receptor inhibitors (EGFRi) and to identify drugs that are cytotoxic once EGFRi ...
Narmeen S. Rashid +14 more
doaj +1 more source
Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer. [PDF]
, 2013 BackgroundPreclinical data indicate EGFR signals through both kinase-dependent and independent pathways and that combining a small-molecule EGFR inhibitor, EGFR antibody, and/or anti-angiogenic agent is synergistic in animal models.MethodsWe conducted a ...
Bastida, Christel +11 more
core +2 more sources
FGFR1 Cooperates with EGFR in Lung Cancer Oncogenesis, and Their Combined Inhibition Shows Improved Efficacy [PDF]
, 2019 Introduction: There is substantial evidence for the onco- genic effects of fi broblast growth factor receptor 1 (FGFR1) in many types of cancer, including lung cancer, but the role of this receptor has not been addressed speci fi cally in lung ...
Carnero Moya, Amancio +11 more
core +1 more source
Measurement and models accounting for cell death capture hidden variation in compound response. [PDF]
, 2020 Cancer cell sensitivity or resistance is almost universally quantified through a direct or surrogate measure of cell number. However, compound responses can occur through many distinct phenotypic outcomes, including changes in cell growth, apoptosis, and
Bae, Song Yi +5 more
core +1 more source
Role and mechanism of hexokinase 2 in erlotinib resistance in non-small cell lung cancer
Di-san junyi daxue xuebao, 2020 Objective To observe the expression of hexokinase 2 (HK2), a key enzyme of glycolysis, in human non-small cell lung cancer (NSCLC) tissues, and to investigate the role and mechanism of HK2 in the resistance of NSCLC to erlotinib. Methods The relationship
YOU Qi, ZHUO Wenlei, CHEN Zhengtang
doaj +1 more source
Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents [PDF]
, 2014 Hepatitis C virus (HCV) is transmitted between hepatocytes via classical cell entry but also uses direct cell-cell transfer to infect neighboring hepatocytes.
A Owsianka +72 more
core +7 more sources
Chinese Medical Journal, 2020 . Background:. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as erlotinib and gefitinib, are widely used to treat non-small cell lung cancer (NSCLC).
Peng-Fei Wu +5 more
doaj +1 more source
Pharmacological Research, 2023 Nearly half of all Asian non-small cell lung cancer (NSCLC) patients harbour epidermal growth factor receptor (EGFR) mutations, and first-generation EGFR tyrosine kinase inhibitors (TKIs) are one of the first-line treatments that have improved the ...
Cong Xu +18 more
doaj +1 more source